Faropenem is a new oral penem with a structure different from current b-lactams including carbapenems. The susceptibility of Streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis to faropenem, a macrolide, a b-lactam, a b-lactam/blactamase inhibitor combination and two fluoroquinolones was investigated. S. pneumoniae was the most susceptible of the three species to faropenem. The MIC 90 s of faropenem against M. catarrhalis and H. influenzae were 0.5 and 1 mg/l, respectively. They were similar to amoxiclav (MIC 90 s of 0.25 and 0.5 mg/l). The quinolones showed strong activity against H. influenzae . A cluster analysis of the activities of amoxycillin and faropenem demonstrated a direct relationship between the two antimicrobial agent's activities and resistance profiles against both S. pneumoniae and H. influenzae . #
Introduction
Faropenem is a new oral penem antimicrobial agent, which has an unsaturated thiazole ring and is a structural hybrid between the penicillin and carbapenem nucleus (Fig. 1 ). It is characterised by potent penicillin binding protein activity and b-lactamase stability. The antibacterial spectrum of faropenem includes Grampositive, Gram-negative and some anaerobic bacteria [1] . In common with other b-lactams, target modifications via altered penicillin-binding proteins (PBPs) have previously been shown to increase the minimum inhibitory concentration (MIC) of faropenem for respiratory tract infections compared with wild type strains [2] .
Faropenem typically shows high affinity for PBPs compared with other agents. Respiratory tract infections are a major cause of morbidity and mortality in the community and hospitals. Streptococcus pneumoniae , Moraxella catarrhalis and Haemophilus influenzae are common causes of lower respiratory tract infections (LRTIs) and upper respiratory tract infections (URTIs). Worldwide, the annual incidence of community-acquired pneumonia (CAP) is estimated to be 1.1 Á/4.0 per 1000 population. In the UK CAP accounts for 5Á/ 12% of cases of LRTIs among adults approximately 20Á/ 42% of which require hospitalisation [3] .
This study compared the in vitro activity of faropenem against S. pneumoniae , M. catarrhalis and H. influenzae isolated in the UK with amoxycillin, amoxiclav, clarithromycin, levofloxacin and ciprofloxacin activity.
Materials and methods

Antimicrobial agents
The following antimicrobial agents were studied: faropenem and ciprofloxacin (Bayer), amoxycillin (CP Pharmaceuticals), amoxiclav (SmithKline Beecham Pharmaceuticals and CP Pharmaceuticals), clarithromycin (Abbott) and levofloxacin (Aventis Pharma Ltd.). The antimicrobial agents were stored and prepared according to the suppliers' instructions. The amoxiclav consisted of fixed concentrations of 2 mg/l of clavulanic acid per plate and doubling dilutions of amoxycillin [4] .
Bacterial strains
S. pneumoniae (n 0/100) from Edinburgh and Leeds, M. catarrhalis (100) from Edinburgh, Leeds and Wales and H. influenzae (100) from Edinburgh and Glasgow, collected between 1997 and 2000, were used in this study. The control strains comprised S. pneumoniae NCTC 13593, Staphylococcus aureus NCTC 6571, H. influenzae NCTC 11931 and a laboratory reference strain of M. catarrhalis .
Susceptibility testing
MICs were determined by standard agar dilution methods according to the BSAC guidelines for sensitivity testing [4] on Columbia agar (Oxoid, Basingstoke) supplemented with 5% defibrinated horse blood for S. pneumoniae and M. catarrhalis and chocolate Columbia agar plates for H. influenzae .
A final concentration of 10 5 cfu per spot of S. pneumoniae and 10 4 cfu per spot of H. influenzae and M. catarrhalis were inoculated onto each plate. The plates were incubated aerobically.
Results
The MICs of faropenem and the comparators are given in Table 1. For S. pneumoniae , faropenem had the lowest MIC 50 (0.008 mg/l) and MIC 90 (0.25 mg/l) of all the antimicrobial agents tested. The faropenem modal MIC against S. pneumoniae was 0.008 mg/l for 39 isolates, which was also the lowest concentration compared with 0.016 mg/l (37 isolates) for amoxiclav, 0.016 Á/0.032 mg/l for amoxycillin against 70 isolates, 0.032 mg/l (42 isolates) for clarithromycin and 1 mg/l for both levofloxacin (48 isolates) and ciprofloxacin (28 isolates). The results suggest that there might be a direct correlation between the sensitivity to amoxycillin and to faropenem. So a cluster analysis of faropenem and amoxycillin MICs against S. pneumoniae , M. catarrhalis and H. influenzae was performed (Fig. 2) . The two graphs have the same distribution patterns and both indicate that there is a direct relationship between amoxycillin and faropenem inhibition of S. pneumoniae and H. influenzae . As resistance to amoxycillin increases, there is a proportional increase in resistance to faropenem. The correlation with M. catarrhalis is less pronounced and does not occur until high levels of penicillin resistance are reached. Thus, strains of S. pneumoniae and in many cases, H. influenzae isolates, resistant to amoxycillin due to alterations in penicillin binding proteins are also able to confer resistance to faropenem [7] . Those strains where b-lactamase resistance is more prominent, particularly M. catarrhalis show less resistance to faropenem.
Discussion
The faropenem results obtained in this study agree with previously reported data and indicate that it has significant activity (MIC 90 5/1 mg/l) against respiratory tract infections such as S. pneumoniae , M. catarrhalis and H. influenzae [5, 6] . The activity of faropenem was usually of a similar level to that of amoxiclav. This is perhaps not surprising as the clavulanic acid component of amoxiclav removes the b-lactamase contribution to amoxycillin resistance and faropenem is b-lactamase stable. This is emphasised by the correlation between amoxycillin and faropenem inhibition shown in Fig. 2 . These cluster analyses show a direct relationship between faropenem and amoxycillin sensitivities demonstrating that faropenem was not capable of over-coming the resistance mechanisms arising from alteration of penicillin binding proteins in S. pneumoniae . The correlation was also quite clear in H. influenzae , where much of the amoxycillin resistance is mediated by mechanisms other than b-lactamase hydrolysis [7] .
There is less obvious correlation in M. catarrhalis , where b-lactamase hydrolysis is a more prominent mechanism of amoxycillin hydrolysis [8] . In this case, there is a major increase in amoxycillin resistance without a significant change in faropenem resistance. It is only after a threshold is reached that further increases in amoxycillin resistance correspond with concomitant increases in faropenem resistance. As anticipated the two quinolones tested had lower MIC 50 and MIC 90 values than all the agents tested for H. influenzae and all the agents except amoxiclav for M. catarrhalis . In these in vitro tests clarithromycin does not perform as well as faropenem against S. pneumoniae or H. influenzae. The results of faropenem demonstrate that it is a potent drug but these results suggest that the acquisition of penicillin resistance would have an adverse effect on faropenem in S. pneumoniae and H. influenzae but less so in M. catarrhalis .
